These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 29733561)

  • 21. Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders.
    Glue P; Medlicott NJ; Harland S; Neehoff S; Anderson-Fahey B; Le Nedelec M; Gray A; McNaughton N
    J Psychopharmacol; 2017 Oct; 31(10):1302-1305. PubMed ID: 28441895
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ketamine: repurposing and redefining a multifaceted drug.
    Potter DE; Choudhury M
    Drug Discov Today; 2014 Dec; 19(12):1848-54. PubMed ID: 25224017
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ketamine and Electroconvulsive Therapy for Depression.
    Andrade C
    J Neurosurg Anesthesiol; 2018 Oct; 30(4):288-289. PubMed ID: 30001277
    [No Abstract]   [Full Text] [Related]  

  • 24. Impact of oral ketamine augmentation on hospital admissions in treatment-resistant depression and PTSD: a retrospective study.
    Hartberg J; Garrett-Walcott S; De Gioannis A
    Psychopharmacology (Berl); 2018 Feb; 235(2):393-398. PubMed ID: 29151192
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral ketamine augmentation for chronic suicidality in treatment-resistant depression.
    De Gioannis A; De Leo D
    Aust N Z J Psychiatry; 2014 Jul; 48(7):686. PubMed ID: 24452289
    [No Abstract]   [Full Text] [Related]  

  • 26. Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: A double-blind, randomized, controlled trial.
    Jafarinia M; Afarideh M; Tafakhori A; Arbabi M; Ghajar A; Noorbala AA; Saravi MA; Agah E; Akhondzadeh S
    J Affect Disord; 2016 Nov; 204():1-8. PubMed ID: 27317968
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The promise of ketamine for treatment-resistant depression: current evidence and future directions.
    DeWilde KE; Levitch CF; Murrough JW; Mathew SJ; Iosifescu DV
    Ann N Y Acad Sci; 2015 May; 1345(1):47-58. PubMed ID: 25649308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of Ketamine in Severe Depression with suicidal ideation - Insights from a Case Study.
    Gurnani T; Khurshid KA
    Asian J Psychiatr; 2017 Oct; 29():112-113. PubMed ID: 29061405
    [No Abstract]   [Full Text] [Related]  

  • 29. Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression: A SPECT Study.
    Sanches RF; de Lima Osório F; Dos Santos RG; Macedo LR; Maia-de-Oliveira JP; Wichert-Ana L; de Araujo DB; Riba J; Crippa JA; Hallak JE
    J Clin Psychopharmacol; 2016 Feb; 36(1):77-81. PubMed ID: 26650973
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comment on Fond and colleagues' systematic review and meta-analysis of ketamine in the treatment of depressive disorders (Psychopharmacology 2014; Jul 20 [Epub ahead of print]).
    McGirr A; Berlim MT
    Psychopharmacology (Berl); 2014 Oct; 231(19):3907-8. PubMed ID: 25176174
    [No Abstract]   [Full Text] [Related]  

  • 31. Ketamine Noninferior to Electroconvulsive Therapy for Depression.
    Harris E
    JAMA; 2023 Jun; 329(23):2011-2012. PubMed ID: 37256574
    [No Abstract]   [Full Text] [Related]  

  • 32. Combination therapy utilizing ketamine and transcranial magnetic stimulation for treatment-resistant depression: a case report.
    Best SR; Griffin B
    Int J Neurosci; 2015 Mar; 125(3):232-4. PubMed ID: 24927244
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
    Feder A; Parides MK; Murrough JW; Perez AM; Morgan JE; Saxena S; Kirkwood K; Aan Het Rot M; Lapidus KA; Wan LB; Iosifescu D; Charney DS
    JAMA Psychiatry; 2014 Jun; 71(6):681-8. PubMed ID: 24740528
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
    Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
    J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravenous ketamine for treatment-resistant major depressive disorder.
    Covvey JR; Crawford AN; Lowe DK
    Ann Pharmacother; 2012 Jan; 46(1):117-23. PubMed ID: 22190250
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapid antidepressant effect of S-ketamine in schizophrenia.
    Bartova L; Papageorgiou K; Milenkovic I; Dold M; Weidenauer A; Willeit M; Winkler D; Kasper S
    Eur Neuropsychopharmacol; 2018 Aug; 28(8):980-982. PubMed ID: 30041987
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.
    aan het Rot M; Collins KA; Murrough JW; Perez AM; Reich DL; Charney DS; Mathew SJ
    Biol Psychiatry; 2010 Jan; 67(2):139-45. PubMed ID: 19897179
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ketamine and Treatment-Resistant Depression.
    Lent JK; Arredondo A; Pugh MA; Austin PN
    AANA J; 2019 Oct; 87(5):411-419. PubMed ID: 31612847
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ketamine as treatment for depression.
    Taiminen T
    Duodecim; 2017; 133(1):52-60. PubMed ID: 29199810
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.
    Patkar AA; Masand PS; Pae CU; Peindl K; Hooper-Wood C; Mannelli P; Ciccone P
    J Clin Psychopharmacol; 2006 Dec; 26(6):653-6. PubMed ID: 17110825
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.